EPS Bio Technology Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

EPS Bio Technology heeft een totaal eigen vermogen van NT$306.8M en een totale schuld van NT$14.3M, wat de schuld-eigenvermogensverhouding op 4.7% brengt. De totale activa en totale passiva bedragen respectievelijk NT$576.2M en NT$269.5M. De EBIT EPS Bio Technology is NT$31.8M waardoor de rentedekking -43.7 is. Het heeft contanten en kortetermijnbeleggingen van NT$177.7M.

Belangrijke informatie

4.7%

Verhouding schuld/eigen vermogen

NT$14.27m

Schuld

Rente dekkingsratio	-43.7x
Contant	NT$177.75m
Aandelen	NT$306.77m
Totaal verplichtingen	NT$269.48m
Totaal activa	NT$576.25m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Should You Or Shouldn't You: A Dividend Analysis on EPS Bio Technology Corp. (GTSM:4183)

Apr 16

Will EPS Bio Technology (GTSM:4183) Multiply In Value Going Forward?

Mar 20

Here's Why We Think EPS Bio Technology's (GTSM:4183) Statutory Earnings Might Be Conservative

Feb 22

Do Fundamentals Have Any Role To Play In Driving EPS Bio Technology Corp.'s (GTSM:4183) Stock Up Recently?

Feb 01

Should EPS Bio Technology Corp. (GTSM:4183) Be Part Of Your Dividend Portfolio?

Jan 04

Is EPS Bio Technology (GTSM:4183) Likely To Turn Things Around?

Dec 14

We Think EPS Bio Technology's (GTSM:4183) Statutory Profit Might Understate Its Earnings Potential

Nov 23

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( NT$397.3M ) 4183 } overtreffen de korte termijn passiva ( NT$159.8M ).

Langlopende schulden: De kortetermijnactiva 4183 ( NT$397.3M ) overtreffen de langetermijnschulden ( NT$109.7M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 4183 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 4183 is de afgelopen 5 jaar gedaald van 9.4% naar 4.7%.

Schuldendekking: De schuld van 4183 wordt goed gedekt door de operationele kasstroom ( 194.2% ).

Rentedekking: 4183 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

EPS Bio Technology Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

EPS Bio Technology Corp. to Report Q3, 2024 Results on Nov 06, 2024

Second quarter 2024 earnings released: EPS: NT$0.34 (vs NT$0.18 in 2Q 2023)

Now 21% overvalued after recent price rise

EPS Bio Technology Corp. to Report Q2, 2024 Results on Aug 07, 2024

Upcoming dividend of NT$0.80 per share

Dividend reduced to NT$0.80

First quarter 2024 earnings released: EPS: NT$0.50 (vs NT$0.10 in 1Q 2023)

EPS Bio Technology Corp. Approves Dividend for the Year 2023

Investor sentiment improves as stock rises 21%

Full year 2023 earnings released: EPS: NT$0.88 (vs NT$1.07 in FY 2022)

EPS Bio Technology Corp., Annual General Meeting, Jun 24, 2024

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Investor sentiment improves as stock rises 23%

Second quarter 2023 earnings released: EPS: NT$0.18 (vs NT$0.21 in 2Q 2022)

EPS Bio Technology Corp. Appoints Lin, Chih-Heng as Research and Development Officer

New major risk - Dividend sustainability

Upcoming dividend of NT$0.98 per share at 4.7% yield

EPS Bio Technology Corp. Approves Dividend Proposal of 2022

Full year 2022 earnings released

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: EPS: NT$0.21 (vs NT$0.27 in 2Q 2021)

EPS Bio Technology Corp. Announces Appointment of Members of Compensation Committee

Upcoming dividend of NT$0.70 per share

Eps Bio Technology Corp. Approves Cash Dividend for the Year 2021, Payable on August 4, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: EPS NT$0.16 (vs NT$0.49 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.27 (vs NT$0.59 in 2Q 2020)

Upcoming dividend of NT$1.20 per share

First quarter 2021 earnings released: NT$0.22 loss per share (vs NT$0.18 profit in 1Q 2020)

Board of Directors Approves Proposal to Distribute Dividends

Should You Or Shouldn't You: A Dividend Analysis on EPS Bio Technology Corp. (GTSM:4183)

Will EPS Bio Technology (GTSM:4183) Multiply In Value Going Forward?

EPS Bio Technology Corp., Annual General Meeting, Jun 28, 2021

Full year 2020 earnings released: EPS NT$1.33 (vs NT$0.78 in FY 2019)

Here's Why We Think EPS Bio Technology's (GTSM:4183) Statutory Earnings Might Be Conservative

Do Fundamentals Have Any Role To Play In Driving EPS Bio Technology Corp.'s (GTSM:4183) Stock Up Recently?

Should EPS Bio Technology Corp. (GTSM:4183) Be Part Of Your Dividend Portfolio?

Is EPS Bio Technology (GTSM:4183) Likely To Turn Things Around?

We Think EPS Bio Technology's (GTSM:4183) Statutory Profit Might Understate Its Earnings Potential

Third quarter 2020 earnings released: EPS NT$0.49

New 90-day low: NT$20.00

First half earnings released

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven